Synlogic | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.19.

EBIT: As of FY2025 Q3, the actual value is USD -1.166 M.

Financial Metrics by Segment

Research and Development

• Three Months Ended September 30, 2025: $8,000
• Three Months Ended September 30, 2024: -$713,000
• Nine Months Ended September 30, 2025: $16,000
• Nine Months Ended September 30, 2024: $9,164,000

General and Administrative

• Three Months Ended September 30, 2025: $818,000
• Three Months Ended September 30, 2024: $1,165,000
• Nine Months Ended September 30, 2025: $2,454,000
• Nine Months Ended September 30, 2024: $5,228,000

Restructuring and Other Charges

• Three Months Ended September 30, 2025: $165,000
• Three Months Ended September 30, 2024: $296,000
• Nine Months Ended September 30, 2025: $196,000
• Nine Months Ended September 30, 2024: $24,790,000

Other Income (Expense)

• Three Months Ended September 30, 2025: -$1,310,000
• Three Months Ended September 30, 2024: $631,000
• Nine Months Ended September 30, 2025: $153,000
• Nine Months Ended September 30, 2024: $16,534,000

Net Loss

• Three Months Ended September 30, 2025: -$2,301,000
• Three Months Ended September 30, 2024: -$117,000
• Nine Months Ended September 30, 2025: -$2,513,000
• Nine Months Ended September 30, 2024: -$22,645,000

Cash Flow

• Net Cash Used in Operating Activities: -$3,436,000 for the nine months ended September 30, 2025; -$31,090,000 for the nine months ended September 30, 2024
• Net Cash Provided by Investing Activities: $167,000 for the nine months ended September 30, 2025; $25,309,000 for the nine months ended September 30, 2024
• Net Cash Provided by Financing Activities: $0 for the nine months ended September 30, 2025; $163,000 for the nine months ended September 30, 2024

Future Outlook and Strategy

• Core Business Focus: Synlogic, Inc. is currently focused on pursuing strategic initiatives to enhance stockholder value, including potential mergers, sales, collaborations, partnerships, and licensing opportunities. The company is actively engaged in a strategic review process and has reduced its workforce significantly, leaving one full-time employee and engaging consultants to support the strategic review and current business operations.
• Non-Core Business: The company has discontinued its Synpheny-3 clinical trial for its lead product candidate, labafenogene marselecobac (SYNB1934), and is evaluating strategic alternatives, including the possibility of a merger or sale of the company.